Sarepta Therapeutics (MEX:SRPT) Long-Term Debt: MXN15,114 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SRPT Sarepta Therapeutics Inc MEX:SRPT
36 GF Score
Price MXN294.00
GF Value MXN2,371.95
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Long-Term Debt?

Sarepta Therapeutics MEX:SRPT 36 Long-Term Debt is MXN15,114 Mil as of Mar. 2026. GuruFocus rates MEX:SRPT with a GF Score™ of 36/100 and a GF Value™ of MXN2,371.95 (Possible Value Trap). The stock has 5 warning signs investors should review.

Sarepta Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was MXN15,114 Mil.

Sarepta Therapeutics's quarterly Long-Term Debt declined from Sep. 2025 (MXN18,989 Mil) to Dec. 2025 (MXN14,926 Mil) but then increased from Dec. 2025 (MXN14,926 Mil) to Mar. 2026 (MXN15,114 Mil).

Sarepta Therapeutics's annual Long-Term Debt increased from Dec. 2023 (MXN19,224 Mil) to Dec. 2024 (MXN23,716 Mil) but then declined from Dec. 2024 (MXN23,716 Mil) to Dec. 2025 (MXN14,926 Mil).

Sarepta Therapeutics  (MEX:SRPT) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Sarepta Therapeutics Long-Term Debt Related Terms

Sarepta Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Sarepta Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics Long-Term Debt Chart

Sarepta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22,501.31 30,107.52 19,223.59 23,715.52 14,926.26

Sarepta Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23,287.34 21,455.08 18,988.93 14,926.26 15,114.32
MEX:SRPT
36GF Score
Sarepta Therapeutics Inc MEX:SRPT
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of MXN15,114 Mil mean?
Sarepta Therapeutics (MEX:SRPT) has a Long-Term Debt of MXN15,114 Mil as of Mar. 2026.
Is Sarepta Therapeutics' Long-Term Debt too high?
Sarepta Therapeutics' current Long-Term Debt is MXN15,114 Mil. Overall, Sarepta Therapeutics has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Long-Term Debt compare to ZYME and BCAX?
Sarepta Therapeutics' Long-Term Debt of MXN15,114 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Sarepta Therapeutics's current Long-Term Debt is MXN15,114 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (MEX:SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is MXN2,371.95, compared to a current price of MXN294.00 — trading 87.6% below its estimated fair value. The current Long-Term Debt is MXN15,114 Mil. Sarepta Therapeutics' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Sarepta Therapeutics (MEX:SRPT), the current Long-Term Debt is MXN15,114 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (MEX:SRPT) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of MXN294.00 is trading 87.6% below its estimated GF Value™ of MXN2,371.95. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for MEX:SRPT:

  • Long-Term Debt: MXN15,114 Mil
  • GF Value™: MXN2,371.95 vs. price of MXN294.00 (87.6% below fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the MEX:SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
36GF Score

Get the complete analysis for MEX:SRPT

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN294.00
Price
MXN2,371.95
GF Value